InvestorsHub Logo
Followers 120
Posts 20403
Boards Moderated 0
Alias Born 06/13/2011

Re: rosemountbomber post# 134

Thursday, 03/14/2024 12:44:04 PM

Thursday, March 14, 2024 12:44:04 PM

Post# of 214
RMB. It's good news if they can keep the new phosphorous lowering drugs out of the dialysis bundle . My understanding is that the bundle ( essentially a fixed price medicare / medicaid will pay for dialysis ) forces patients to the lowest cost generics.

ChatGPT
The dialysis bundle itself does not directly limit access to brand drugs. Instead, it focuses on optimizing care practices and resource utilization in the management of patients undergoing dialysis treatment, particularly those with end-stage renal disease (ESRD). However, there are broader healthcare policies and initiatives that may indirectly impact access to brand drugs for dialysis patients.

One of the ways access to brand drugs can be limited is through healthcare payers, such as insurance companies or government payers like Medicare or Medicaid, implementing formularies that preferentially cover generic drugs over brand-name drugs. Formularies are lists of medications that insurers cover, and they often include tiered structures where generics are placed on lower-cost tiers with lower copayments or coinsurance compared to brand-name drugs.
[/I]
And
The Medicare End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) is used to reimburse dialysis facilities for Medicare beneficiaries with ESRD. This system sets a base rate for dialysis treatments, with adjustments made for factors such as patient demographics, comorbidities, and geographic location.[/I]
---------------------------------------------------
Little confusing but generally if the new drugs are in the bundle it limits what the govt will cover if at all ...just my take


Looks like a good funding deal this am .
Private placement with existing funds plus some new ones added . Vivo still in and added ...they in my experience ( SLNO ) are cutting edge in these niche speciality drugs .
This final trial is open label. The early patients enrolled have already completed most of the trial ...if not all of it.
I'm speculating that these investors must have had some indication that things were going well in the trial
JMO
Kiwi
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent UNCY News